Argenx
ARGX
#824
Rank
$23.34 B
Marketcap
$393.72
Share price
-1.22%
Change (1 day)
7.44%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Revenue for Argenx (ARGX)

Revenue in 2023 (TTM): $1.22 B

According to Argenx 's latest financial reports the company's current revenue (TTM) is $1.22 B. an increase over the years 2022 revenue that were of $0.41 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Argenx from 2013 to 2023

Annual revenue

Year Revenue Change
2023$1.22 B198.56%
2022$0.41 B
2019$87.59 M201.19%
2018$29.08 M-42.19%
2017$50.31 M194.21%
2016$17.1 M105.72%
2015$8.31 M43.78%
2014$5.78 M16.7%
2013$4.95 M